Conformational Changes Relevant to Channel Activity and Folding within the first Nucleotide Binding Domain of the Cystic Fibrosis Transmembrane Conductance Regulator*

Background: The CFTR chloride channel undergoes conformational changes during its gating cycle. Results: H620Q mutation associated with increased channel Po, and the corrector/potentiator CFFT-001 both lead to similar conformational shifts in NBD1. Conclusion: There is an intrinsic conformational equilibrium within NBD1 that is correlated with channel activity. Significance: Conformational fluctuations within NBD1 are fundamental to CFTR regulation. Deletion of Phe-508 (F508del) in the first nucleotide binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR) leads to defects in folding and channel gating. NMR data on human F508del NBD1 indicate that an H620Q mutant, shown to increase channel open probability, and the dual corrector/potentiator CFFT-001 similarly disrupt interactions between β-strands S3, S9, and S10 and the C-terminal helices H8 and H9, shifting a preexisting conformational equilibrium from helix to coil. CFFT-001 appears to interact with β-strands S3/S9/S10, consistent with docking simulations. Decreases in Tm from differential scanning calorimetry with H620Q or CFFT-001 suggest direct compound binding to a less thermostable state of NBD1. We hypothesize that, in full-length CFTR, shifting the conformational equilibrium to reduce H8/H9 interactions with the uniquely conserved strands S9/S10 facilitates release of the regulatory region from the NBD dimerization interface to promote dimerization and thereby increase channel open probability. These studies enabled by our NMR assignments for F508del NBD1 provide a window into the conformational fluctuations within CFTR that may regulate function and contribute to folding energetics.

[1]  J. Clancy,et al.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation , 2011, Thorax.

[2]  B. Nilius,et al.  Characterization of mutations located in exon 18 of the CFTR gene , 1998, FEBS letters.

[3]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[4]  A. Evagelidis,et al.  Phosphorylation of CFTR by PKA promotes binding of the regulatory domain , 2005, The EMBO journal.

[5]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[6]  J. Clancy,et al.  Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.

[7]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[8]  Jinglan Zhou,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[9]  L. Kay,et al.  Improved 1HN-detected triple resonance TROSY-based experiments , 1999, Journal of biomolecular NMR.

[10]  M. Welsh,et al.  Regulation of the Cystic Fibrosis Transmembrane Conductance Regulator Cl− Channel by Its R Domain* , 2001, The Journal of Biological Chemistry.

[11]  Isabelle Callebaut,et al.  Molecular models of the open and closed states of the whole human CFTR protein , 2009, Cellular and Molecular Life Sciences.

[12]  D. Sheppard,et al.  Gating of the CFTR Cl− channel by ATP‐driven nucleotide‐binding domain dimerisation , 2009, The Journal of physiology.

[13]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[14]  J. M. Sauder,et al.  Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry. , 2010, Journal of molecular biology.

[15]  Gordon S. Rule,et al.  Fundamentals of Protein NMR Spectroscopy , 2005 .

[16]  K Wüthrich,et al.  TROSY in triple-resonance experiments: new perspectives for sequential NMR assignment of large proteins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Hockney,et al.  Quiet high resolution computer models of a plasma , 1974 .

[18]  L. Tsui,et al.  Identification of the cystic fibrosis gene: genetic analysis. , 1989, Science.

[19]  D. van der Spoel,et al.  A temperature predictor for parallel tempering simulations. , 2008, Physical chemistry chemical physics : PCCP.

[20]  A. Evagelidis,et al.  PKC phosphorylation modulates PKA-dependent binding of the R domain to other domains of CFTR. , 2008, American journal of physiology. Cell physiology.

[21]  Zhengrong Yang,et al.  Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis , 2010, Protein science : a publication of the Protein Society.

[22]  J. Riordan,et al.  Identification of the Cystic Fibrosis Gene : Chromosome Walking and Jumping Author ( s ) : , 2008 .

[23]  J. Forman-Kay,et al.  CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices , 2007, Nature Structural &Molecular Biology.

[24]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[25]  H. A. Berger,et al.  Identification of revertants for the cystic fibrosis ΔF508 mutation using STE6-CFTR chimeras in yeast , 1993, Cell.

[26]  Angus C Nairn,et al.  In vivo phosphorylation of CFTR promotes formation of a nucleotide‐binding domain heterodimer , 2006, The EMBO journal.

[27]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[28]  G. Lukács,et al.  Limited proteolysis as a probe for arrested conformational maturation of ΔF508 CFTR , 1998, Nature Structural Biology.

[29]  R. Dror,et al.  Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.

[30]  John F Hunt,et al.  ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. , 2002, Molecular cell.

[31]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[32]  J. Marsh,et al.  Sensitivity of secondary structure propensities to sequence differences between α‐ and γ‐synuclein: Implications for fibrillation , 2006 .

[33]  F. van Goor,et al.  Ivacaftor potentiation of multiple CFTR channels with gating mutations. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[34]  J. Wine,et al.  Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation (*) , 1996, The Journal of Biological Chemistry.

[35]  J. M. Sauder,et al.  Impact of the ΔF508 Mutation in First Nucleotide-binding Domain of Human Cystic Fibrosis Transmembrane Conductance Regulator on Domain Folding and Structure* , 2005, Journal of Biological Chemistry.

[36]  B. Nilius,et al.  Phosphorylation site independent single R‐domain mutations affect CFTR channel activity , 1998, FEBS letters.

[37]  Pascal Barbry,et al.  Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.

[38]  M. Hodson,et al.  Identification of the cystic fibrosis gene. , 1990, BMJ.

[39]  Robert C. Edgar,et al.  MUSCLE: multiple sequence alignment with high accuracy and high throughput. , 2004, Nucleic acids research.

[40]  Julie D Forman-Kay,et al.  NMR evidence for differential phosphorylation‐dependent interactions in WT and ΔF508 CFTR , 2010, The EMBO journal.

[41]  Woody Sherman,et al.  Use of an Induced Fit Receptor Structure in Virtual Screening , 2006, Chemical biology & drug design.

[42]  J. M. Sauder,et al.  Structure of nucleotide‐binding domain 1 of the cystic fibrosis transmembrane conductance regulator , 2004, The EMBO journal.

[43]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[44]  Bruce A. Johnson,et al.  NMR View: A computer program for the visualization and analysis of NMR data , 1994, Journal of biomolecular NMR.

[45]  A S Verkman,et al.  CFTR: folding, misfolding and correcting the ΔF508 conformational defect. , 2012, Trends in molecular medicine.

[46]  A. Nairn,et al.  Functional Roles of Nonconserved Structural Segments in CFTR's NH2-terminal Nucleotide Binding Domain , 2005, The Journal of general physiology.

[47]  Feng Ding,et al.  Multiscale modeling of nucleosome dynamics. , 2007, Biophysical journal.

[48]  John F Hunt,et al.  Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant. , 2010, Protein engineering, design & selection : PEDS.

[49]  M. Welsh,et al.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.

[50]  Zhengrong Yang,et al.  Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide‐binding domain 1 , 2010, Protein science : a publication of the Protein Society.

[51]  James O. Wrabl,et al.  The role of protein conformational fluctuations in allostery, function, and evolution. , 2011, Biophysical chemistry.

[52]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[53]  J. Forman-Kay,et al.  NMR spectroscopy to study the dynamics and interactions of CFTR. , 2011, Methods in molecular biology.

[54]  Kai Du,et al.  Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. , 2005, The Journal of clinical investigation.

[55]  Lisa Yan,et al.  Fully Automated Molecular Mechanics Based Induced Fit Protein—Ligand Docking Method. , 2009 .

[56]  J. Mornon,et al.  C Terminus of Nucleotide Binding Domain 1 Contains Critical Features for Cystic Fibrosis Transmembrane Conductance Regulator Trafficking and Activation* , 2010, The Journal of Biological Chemistry.

[57]  Pradeep Kota,et al.  Regulatory insertion removal restores maturation, stability and function of DeltaF508 CFTR. , 2010, Journal of molecular biology.

[58]  L. D. Howell,et al.  Stimulatory and inhibitory protein kinase C consensus sequences regulate the cystic fibrosis transmembrane conductance regulator , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Amaral,et al.  Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. , 2008, Chemistry & biology.

[60]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[61]  L. Tsui,et al.  Identification of the cystic fibrosis gene: chromosome walking and jumping. , 1989, Science.

[62]  B. Kemp,et al.  Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase. , 2000, The Journal of clinical investigation.

[63]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.